Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

CD44 is a glycoprotein expressed in leucocytes and a marker of leukemia-initiating cells, being shown to be important in the pathogenesis of T cell acute lymphoblastic leukemia (T-ALL). In this study, we have (i) identified the aberrant antigenic pattern of CD44 and its isoform CD44v6 in T-ALL; (ii) tested the association with different T-cell subtypes and genomic alterations; (iii) identified the impact of CD44 status in T-ALL outcome. Samples from 184 patients (123 T-ALL and 61 AML; <19 years) were analyzed throughout multiparametric flow cytometry. Mutations in <i>N/KRAS, NOTCH1, FBXW7</i> as well as <i>STIL-TAL1</i> and <i>TLX3</i> rearrangements were detected using standard molecular techniques. CD44 expression was characterized in all T-ALL and AML cases. Compared with AML samples in which the median fluorescence intensity (MFI) was 79.1 (1-1272), T-ALL was relatively low, with MFI 43.2 (1.9-1239); CD44v6 expression was rarely found, MFI 1 (0.3-3.7). T-ALL immature subtypes (mCD3/CD1a<sup>neg</sup>) had a lower CD44 expression, MFI 57.5 (2.7-866.3), whereas mCD3/TCRγδ<sup>pos</sup> cases had higher expressions, MFI 99.9 (16.4-866.3). <i>NOTCH1</i> <sup>mut</sup> and <i>STIL-TAL1</i> were associated with low CD44 expression, whereas <i>N/KRAS</i> <sup>mut</sup> and <i>FBXW7</i> <sup>mut</sup> cases had intermediate expression. In relation to clinical features, CD44 expression was associated with tumor infiltrations (<i>p</i> = 0.065). However, no association was found with initial treatment responses and overall survival prediction. Our results indicate that CD44 is aberrantly expressed in T-ALL being influenced by different genomic alterations. Unraveling this intricate mechanism is required to place CD44 as a therapeutic target in T-ALL.

Original publication




Journal article


Frontiers in oncology


Frontiers Media SA

Publication Date





488 - 488